https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr e12566)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr e12566)2016-06-05 12:12:422019-07-17 12:13:35Dendritic cells-based vaccine to inhibit triple-negative breast cancer cells proliferation.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1086)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1086)2016-06-05 12:10:572019-07-17 12:11:24Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1081)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1081)2016-06-05 12:10:062019-07-17 12:10:27Impact of CD8 stromal lymphocytes in BC patients with the addition of autologous dendritic CELL vaccination to neoadjuvant chemotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-21 / Int. J. Radiat. Oncol. Biol. Phys. 2016 Apr;94(5):1073-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-21 / Int. J. Radiat. Oncol. Biol. Phys. 2016 Apr;94(5):1073-872015-12-21 00:00:002015-12-21 00:00:00Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-11-02 / Radiother Oncol 2015 Nov;117(2):223-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-11-02 / Radiother Oncol 2015 Nov;117(2):223-82015-11-02 00:00:002015-11-02 00:00:00Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Nat. Med. 2015 Oct;21(10):1128-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Nat. Med. 2015 Oct;21(10):1128-382015-10-01 00:00:002015-10-01 00:00:00Natural and therapy-induced immunosurveillance in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / 2016 Feb;5(2):e1078057
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / 2016 Feb;5(2):e10780572015-08-27 00:00:002015-08-27 00:00:00Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-13 / Clin Transl Oncol 2016 Jan;18(1):82-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-13 / Clin Transl Oncol 2016 Jan;18(1):82-72015-08-13 00:00:002015-08-13 00:00:00Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-02 / Front Immunol 2015;6:271
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-02 / Front Immunol 2015;6:2712015-06-02 00:00:002015-06-02 00:00:00Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
